Skip to content
10-Q

Quarterly Report

Intra-Cellular Therapies, Inc.

0001628280-24-035386

← back to feed
Filed
Aug 7, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 5, 2024 105.67M sh
Shares Diluted Q2 2024 · Jun 30, 2024 103.72M sh
Shares Diluted Q2 2024 · Jun 30, 2024 100.3M sh
Shares Diluted Q2 2024 · Jun 30, 2023 95.95M sh
Shares Diluted Q2 2024 · Jun 30, 2023 95.54M sh
Capex Q2 2024 · Jun 30, 2024 $53K
Capex Q2 2024 · Jun 30, 2023 $0
Operating Cash Flow Q2 2024 · Jun 30, 2024 −$33.57M
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$96.87M
Cash And Equivalents Q2 2024 · Jun 30, 2024 $693.31M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $147.77M
Cash And Equivalents Q2 2024 · Jun 30, 2023 $142.26M
Stockholders Equity Q2 2024 · Jun 30, 2024 $1.14B
Stockholders Equity Q2 2024 · Mar 31, 2024 $599.5M
Stockholders Equity Q2 2024 · Dec 31, 2023 $591.42M
Stockholders Equity Q2 2024 · Jun 30, 2023 $607.09M
Stockholders Equity Q2 2024 · Mar 31, 2023 $627.61M
Stockholders Equity Q2 2024 · Dec 31, 2022 $656.07M
Current Liabilities Q2 2024 · Jun 30, 2024 $161.78M
Current Liabilities Q2 2024 · Dec 31, 2023 $123.55M
Total Liabilities Q2 2024 · Jun 30, 2024 $175.89M
Total Liabilities Q2 2024 · Dec 31, 2023 $136.87M
Current Assets Q2 2024 · Jun 30, 2024 $1.26B
Current Assets Q2 2024 · Dec 31, 2023 $667.8M
Total Assets Q2 2024 · Jun 30, 2024 $1.32B
Total Assets Q2 2024 · Dec 31, 2023 $728.3M
Eps Diluted Q2 2024 · Jun 30, 2024 −$0.16
Eps Diluted Q2 2024 · Jun 30, 2024 −$0.31
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.45
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.91
Eps Basic Q2 2024 · Jun 30, 2024 −$0.16
Eps Basic Q2 2024 · Jun 30, 2024 −$0.31
Eps Basic Q2 2024 · Jun 30, 2023 −$0.45
Eps Basic Q2 2024 · Jun 30, 2023 −$0.91
Rd Expense Q2 2024 · Jun 30, 2024 $56.18M
Rd Expense Q2 2024 · Jun 30, 2024 $99.02M
Rd Expense Q2 2024 · Jun 30, 2023 $49.79M
Rd Expense Q2 2024 · Jun 30, 2023 $87.82M
Net Income Q2 2024 · Jun 30, 2024 −$16.22M
Net Income Q2 2024 · Jun 30, 2024 −$31.47M
Net Income Q2 2024 · Mar 31, 2024 −$15.25M
Net Income Q2 2024 · Jun 30, 2023 −$42.78M
Net Income Q2 2024 · Jun 30, 2023 −$86.84M
Net Income Q2 2024 · Mar 31, 2023 −$44.05M
Operating Income Q2 2024 · Jun 30, 2024 −$27.72M
Operating Income Q2 2024 · Jun 30, 2024 −$48.68M
Operating Income Q2 2024 · Jun 30, 2023 −$47.18M
Operating Income Q2 2024 · Jun 30, 2023 −$95.57M
Revenue Q2 2024 · Jun 30, 2024 $161.39M
Revenue Q2 2024 · Jun 30, 2024 $306.25M
Revenue Q2 2024 · Jun 30, 2023 $110.79M
Revenue Q2 2024 · Jun 30, 2023 $206.1M